BRPI0811859A2 - Sais monoclorídricos de um inibidor de histona desacetilase - Google Patents

Sais monoclorídricos de um inibidor de histona desacetilase

Info

Publication number: BRPI0811859A2
Authority: BR; Brazil
Prior art keywords: monocloridic; disacetilase; histone; inhibitor; salts
Prior art date: 2007-05-14

Application number

BRPI0811859-0A2A

Other languages

English (en)

Inventor

Julius W J Dickens

Ioannes Nicolaos Houpis

Yolande Lydia Lang

Carina Leys

Sigrid Carl Maria Stokbroekx

Johan Erwin Edmond Weerts

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-14

Filing date

2008-05-13

Publication date

2014-11-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38659779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0811859(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-05-13 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2014-11-18 Publication of BRPI0811859A2 publication Critical patent/BRPI0811859A2/pt

2020-02-11 Publication of BRPI0811859B1 publication Critical patent/BRPI0811859B1/pt

2021-05-25 Publication of BRPI0811859B8 publication Critical patent/BRPI0811859B8/pt

Links

108010033040 Histones Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Enzymes And Modification Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

BRPI0811859A 2007-05-14 2008-05-13 sal monoclorídrico de um inibidor de histona desacetilase, seu uso e processo de preparação BRPI0811859B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US91782107P	2007-05-14	2007-05-14
EP07108176.4		2007-05-14
EP07108176		2007-05-14
EP60/917,821		2007-05-14
PCT/EP2008/055804 WO2008138918A1 (en)	2007-05-14	2008-05-13	Mono-hydrochloric salts of an inhibitor of histone deacetylase

Publications (3)

Publication Number	Publication Date
BRPI0811859A2 true BRPI0811859A2 (pt)	2014-11-18
BRPI0811859B1 BRPI0811859B1 (pt)	2020-02-11
BRPI0811859B8 BRPI0811859B8 (pt)	2021-05-25

Family

ID=38659779

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0811859A BRPI0811859B8 (pt)	2007-05-14	2008-05-13	sal monoclorídrico de um inibidor de histona desacetilase, seu uso e processo de preparação

Country Status (32)

Country	Link
US (2)	US20100130523A1 (pt)
EP (1)	EP2155677B1 (pt)
JP (1)	JP2010526851A (pt)
KR (1)	KR101540679B1 (pt)
CN (1)	CN101679256B (pt)
AP (1)	AP2717A (pt)
AR (2)	AR066550A1 (pt)
AU (1)	AU2008250047B2 (pt)
BR (1)	BRPI0811859B8 (pt)
CA (1)	CA2683195C (pt)
CL (1)	CL2008001390A1 (pt)
CO (1)	CO6140031A2 (pt)
CR (1)	CR11163A (pt)
CY (1)	CY1115837T1 (pt)
DK (1)	DK2155677T3 (pt)
EA (1)	EA018326B1 (pt)
EC (1)	ECSP099729A (pt)
ES (1)	ES2525456T3 (pt)
HR (1)	HRP20141180T1 (pt)
IL (1)	IL202042A0 (pt)
JO (1)	JO2959B1 (pt)
MX (1)	MX2009012332A (pt)
NZ (1)	NZ599674A (pt)
PA (1)	PA8780301A1 (pt)
PL (1)	PL2155677T3 (pt)
PT (1)	PT2155677E (pt)
RS (1)	RS53672B1 (pt)
SG (1)	SG182986A1 (pt)
SI (1)	SI2155677T1 (pt)
TW (1)	TWI414294B (pt)
UA (1)	UA100510C2 (pt)
WO (1)	WO2008138918A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009015917A2 (en)	2007-05-14	2009-02-05	F. Hoffmann-La Roche Ag	Dihydroquinone and dihydronaphthridine inhibitors of jnk

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5924990B2 (ja) *	1979-11-21	1984-06-13	協和醗酵工業株式会社	新規なピペリジン誘導体
DE69620445T2 (de)	1995-12-08	2002-12-12	Janssen Pharmaceutica N.V., Beerse	(imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
CA2570903C (en) *	2004-07-26	2013-09-17	Applied Research Systems Ars Holding N.V.	N-hydroxyamide derivatives and use thereof
US8193205B2 (en) *	2004-07-28	2012-06-05	Janssen Pharmaceutica N.V.	Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase

2008
- 2008-05-06 JO JO2008202A patent/JO2959B1/en active
- 2008-05-12 PA PA20088780301A patent/PA8780301A1/es unknown
- 2008-05-12 CL CL2008001390A patent/CL2008001390A1/es unknown
- 2008-05-13 PT PT87502522T patent/PT2155677E/pt unknown
- 2008-05-13 DK DK08750252.2T patent/DK2155677T3/en active
- 2008-05-13 PL PL08750252T patent/PL2155677T3/pl unknown
- 2008-05-13 MX MX2009012332A patent/MX2009012332A/es active IP Right Grant
- 2008-05-13 CA CA2683195A patent/CA2683195C/en active Active
- 2008-05-13 EP EP08750252.2A patent/EP2155677B1/en active Active
- 2008-05-13 NZ NZ599674A patent/NZ599674A/xx unknown
- 2008-05-13 TW TW097117494A patent/TWI414294B/zh active
- 2008-05-13 CN CN2008800163514A patent/CN101679256B/zh active Active
- 2008-05-13 AR ARP080102021A patent/AR066550A1/es active IP Right Grant
- 2008-05-13 SI SI200831339T patent/SI2155677T1/sl unknown
- 2008-05-13 AP AP2009005039A patent/AP2717A/xx active
- 2008-05-13 BR BRPI0811859A patent/BRPI0811859B8/pt active IP Right Grant
- 2008-05-13 AU AU2008250047A patent/AU2008250047B2/en active Active
- 2008-05-13 SG SG2012048781A patent/SG182986A1/en unknown
- 2008-05-13 US US12/598,743 patent/US20100130523A1/en not_active Abandoned
- 2008-05-13 RS RS20140662A patent/RS53672B1/sr unknown
- 2008-05-13 ES ES08750252.2T patent/ES2525456T3/es active Active
- 2008-05-13 UA UAA200910196A patent/UA100510C2/ru unknown
- 2008-05-13 KR KR1020097021648A patent/KR101540679B1/ko active Active
- 2008-05-13 JP JP2010507895A patent/JP2010526851A/ja active Pending
- 2008-05-13 EA EA200971031A patent/EA018326B1/ru unknown
- 2008-05-13 HR HRP20141180AT patent/HRP20141180T1/hr unknown
- 2008-05-13 WO PCT/EP2008/055804 patent/WO2008138918A1/en not_active Ceased
2009
- 2009-09-30 CO CO09107340A patent/CO6140031A2/es unknown
- 2009-11-11 IL IL202042A patent/IL202042A0/en active IP Right Grant
- 2009-11-11 EC EC2009009729A patent/ECSP099729A/es unknown
- 2009-12-14 CR CR11163A patent/CR11163A/es not_active Application Discontinuation
2012
- 2012-05-30 US US13/483,678 patent/US8759519B2/en active Active
2014
- 2014-12-17 CY CY20141101062T patent/CY1115837T1/el unknown
2020
- 2020-03-13 AR ARP200100716A patent/AR118361A2/es active IP Right Grant

Also Published As

Publication number	Publication date
KR101540679B1 (ko)	2015-07-30
AR118361A2 (es)	2021-09-29
EP2155677A1 (en)	2010-02-24
EA200971031A1 (ru)	2010-04-30
TW200914024A (en)	2009-04-01
ECSP099729A (es)	2009-12-28
KR20100015647A (ko)	2010-02-12
AU2008250047B2 (en)	2013-01-17
CN101679256A (zh)	2010-03-24
HK1140479A1 (en)	2010-10-15
CR11163A (es)	2010-05-27
CO6140031A2 (es)	2010-03-19
NZ599674A (en)	2013-02-22
CA2683195A1 (en)	2008-11-20
US20100130523A1 (en)	2010-05-27
CL2008001390A1 (es)	2008-11-21
EP2155677B1 (en)	2014-10-01
WO2008138918A1 (en)	2008-11-20
MX2009012332A (es)	2009-12-01
DK2155677T3 (en)	2015-01-05
IL202042A0 (en)	2010-06-16
PT2155677E (pt)	2014-12-23
UA100510C2 (ru)	2013-01-10
BRPI0811859B8 (pt)	2021-05-25
CA2683195C (en)	2016-08-09
SI2155677T1 (sl)	2015-01-30
US8759519B2 (en)	2014-06-24
CY1115837T1 (el)	2017-01-25
BRPI0811859B1 (pt)	2020-02-11
PL2155677T3 (pl)	2015-03-31
AU2008250047A1 (en)	2008-11-20
US20120289527A1 (en)	2012-11-15
PA8780301A1 (es)	2008-12-18
EA018326B1 (ru)	2013-07-30
AR066550A1 (es)	2009-08-26
JO2959B1 (en)	2016-03-15
RS53672B1 (sr)	2015-04-30
JP2010526851A (ja)	2010-08-05
HRP20141180T1 (hr)	2015-02-13
AP2009005039A0 (en)	2009-12-31
CN101679256B (zh)	2013-06-26
TWI414294B (zh)	2013-11-11
AP2717A (en)	2013-07-31
SG182986A1 (en)	2012-08-30
ES2525456T3 (es)	2014-12-23

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-02-12	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-04-09	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2019-08-13	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-12-03	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-02-11	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/05/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

Publication	Publication Date	Title
NO2021013I1 (no)	2021-03-23	filgotinib or a salt thereof
PT2296464E (pt)	2015-07-13	Sais e polimorfos de um composto de tetraciclina
CY2020023I2 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
BRPI0817860A2 (pt)	2019-09-24	inibidores de histona deacetilase
CY2017016I1 (el)	2017-07-12	Αναστολεις πρωτεασωματος
BRPI0922466A2 (pt)	2018-10-23	sais
BRPI0806898A2 (pt)	2015-07-14	Inibidores de mek
BRPI0910232A2 (pt)	2015-09-29	formas de sais inibidores do mtor
DK3208269T3 (da)	2021-10-11	Inhibitorer af c-fms-kinase
EP2305306A4 (en)	2012-08-29	NEURO INVASION INHIBITOR
DK2041138T3 (da)	2014-08-11	Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da)	2011-06-27	Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
CR10831A (es)	2009-06-18	INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2091945T3 (da)	2014-04-22	Nye inhibitorer af glutaminylcyclase
BRPI0918564A2 (pt)	2015-12-01	inibidores
SMP201000116B (it)	2011-09-09	Inibitori di diacetilasi B a base di idrossamato
SMT201700121B (it)	2017-03-08	Sale amorfo di un inibitore macrociclico di hcv
BRPI0821247A2 (pt)	2015-06-16	Inibidores de histona deacetilase
DK2066662T3 (da)	2013-01-07	Serinhydrolaseinhibitorer
DK2506840T3 (da)	2021-04-12	Anvendelser af hæmmere af hypoksi-fremkaldende faktorer
FR2911341B1 (fr)	2013-01-11	Inhibiteur de corrosion
NO20071562L (no)	2008-09-29	Beleggingssammensetning
EP2177529A4 (en)	2011-04-20	NEW SECRETASE HEMMER
DK1991718T3 (da)	2013-10-28	Korrosionsinhibitorer
BR112012001586A2 (pt)	2015-09-01	Inibidores de fosfolipase d seletivos a isoforma